CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Grade 3 Endometrial Cancer — The Awkward Middle Case
Grade 3 endometrioid cancer occupies an uncomfortable position, and it is worth naming that directly. By histological type it belongs with the common, favourable endometrioid cancers. By behaviour it sits much closer to the aggressive ones, and it is frequently managed alongside them. Women with this diagnosis often read the reassuring material about Type 1 endometrial cancer and find that very little of it seems to apply — which is confusing rather than reassuring. This page is about why the grade changes so much, and about the one test that can change the picture substantially in either direction.
- More than half solid growth — the tumour has largely stopped forming glands
- Endometrioid by type, high grade by behaviour — which is why it is grouped with the aggressive cancers
- Treatment after surgery is usual — radiation, and often chemotherapy, rather than nothing
- Molecular testing matters most here — POLE and p53 can move the answer either way
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Grade 3 Actually Describes
Normal endometrium is made of glands. Endometrioid cancer keeps making them — that is what makes it endometrioid. Grade measures how much of that ability the tumour has lost.
The pathologist estimates how much of the tumour grows as solid sheets rather than forming glands. More than half solid, and the tumour is Grade 3. There is also a second route: if the cell nuclei look markedly abnormal in a way that does not fit the architectural pattern, the grade is raised by one.
- Losing structure is losing restraint. A tumour that has abandoned the architecture of the tissue it came from tends to behave less like that tissue in every other respect too — growing faster, invading deeper, and travelling more readily.
- The measurable consequences. Grade 3 tumours have a higher rate of deep invasion into the muscle wall, more lymphovascular space invasion, and a greater chance of lymph node involvement than Grade 1 and 2 tumours at the same stage.
- Which is why the grouping changes. Increasingly, reports use “low grade” for Grades 1 and 2 together and “high grade” for Grade 3 — because that two-way split tracks behaviour better than the three-point scale, and because separating Grade 1 from Grade 2 is one of the less reproducible judgements in pathology.
- Grade can change after surgery. A biopsy samples a fragment; the whole uterus may show a different predominant grade. Revisions go both ways. See endometrial cancer grades.
Did You Know? Grade 3 is the group in which molecular testing does the most work, and it is one of the few places in oncology where a test can lead to less treatment rather than more. A POLE-mutated tumour carries an exceptionally favourable outlook even when it looks aggressive down the microscope and is graded 3 — and European guidance supports de-escalating adjuvant treatment in early-stage POLE-mutated disease rather than treating on the strength of the grade. The reverse is equally true: a p53-abnormal Grade 3 tumour is managed as high risk regardless. Two women with identical-looking pathology can therefore reasonably receive quite different recommendations, and the difference is invisible under a microscope. Sources: ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; FIGO staging system for cancer of the endometrium, 2023 revision; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Where Grade 3 Sits Between the Two Groups
This is the table that explains why the material you have read may not have matched your situation.
| Grade 1–2 endometrioid | Grade 3 endometrioid | Serous / clear cell | |
|---|---|---|---|
| Histological type | Endometrioid | Endometrioid | Non-endometrioid |
| Oestrogen-driven | Yes | Often, though less consistently | No |
| Hormone receptors | Frequently positive | Variable — worth testing | Usually negative |
| Deep invasion / node spread | Less common | More common | More common |
| Treatment after surgery | Frequently none at early stage | Usually recommended | Usually recommended, including chemotherapy |
| Fertility-sparing possible | Yes, for Grade 1 confined to the lining | No | No |
| Molecular testing | Informative | Decisive — POLE and p53 can move the plan either way | Confirms high risk; MMR opens immunotherapy |
The practical consequence of that middle column: if you have Grade 3 endometrioid cancer, general reassurance about “the common type” does not straightforwardly apply to you, and neither does everything written about serous carcinoma. Your situation genuinely sits between them, and the molecular result is what resolves where.
Has Your Tumour Had POLE and p53 Testing?
In Grade 3 disease these can change the recommendation substantially — in either direction. Worth checking before decisions are finalised.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Is the Group Where One Test Can Change the Plan
And unusually, it can change it towards less treatment rather than more.
Why testing matters most here
How Each Molecular Group Changes the Picture
Four groups, and in Grade 3 disease they spread the outlook wider than the grade itself does. All are established from tissue already removed.
POLE-mutated — the favourable surprise
A mutation in the POLE gene disables part of the cell's DNA proofreading, producing tumours with enormous numbers of mutations. Counter-intuitively these behave exceptionally well, with very low recurrence rates even at Grade 3 and even with features that would otherwise be worrying. The likely explanation is that a tumour carrying so many mutations is highly visible to the immune system. European guidance supports omitting adjuvant treatment in early-stage POLE-mutated disease, making this one of very few molecular findings that reduces recommended treatment. If you have Grade 3 disease, POLE status is worth asking about by name.
p53-abnormal — the unfavourable one
An abnormal p53 result indicates loss of a central tumour-suppressor mechanism and identifies a group with a materially worse outlook. A p53-abnormal Grade 3 endometrioid tumour is managed as high risk regardless of how modest the stage appears, generally with both chemotherapy and radiation. This group overlaps substantially with the serous carcinomas, which is part of the evidence that the old Type 1 and Type 2 division was cutting the disease in the wrong place. It is the finding that most often escalates treatment.
Mismatch repair deficient — intermediate, with a treatment implication
Common in endometrial cancer generally and carrying an intermediate outlook. Its importance in Grade 3 disease is twofold. It identifies women who may respond to checkpoint inhibitor immunotherapy if disease is advanced or recurs, which is a genuine option that did not exist a decade ago. And a minority of deficient results signal Lynch syndrome, with implications for the whole family. See MMR and MSI testing and Lynch syndrome.
No specific molecular profile — the residual group
Tumours falling into none of the above categories. Outcomes here are intermediate and are driven more by the conventional factors — stage, depth of invasion, lymphovascular space invasion — than by molecular findings. In practice this means the traditional risk assessment continues to apply, and treatment recommendations follow the pathological features rather than being modified by biology. It is the largest group in most series.
Why this ordering matters more than the grade
The reason molecular classification was incorporated into the 2023 FIGO staging system is that these four groups separate outcomes more sharply than histological grade does. Two Grade 3 endometrioid tumours that look identical under a microscope, at the same stage, can sit in the POLE-mutated and p53-abnormal groups respectively — and face genuinely different situations with genuinely different recommended treatment. That is a strong argument for ensuring the testing is complete before adjuvant decisions are finalised.
What to ask for, specifically
Ask whether POLE sequencing, p53 immunohistochemistry and mismatch repair testing have all been performed, and what each showed. All three are done on tissue already removed at surgery and require no new procedure. POLE sequencing in particular is not universally available in every centre and is sometimes omitted, which matters because it is the finding most likely to spare you treatment. If any are missing, ask whether stored tissue can be tested before the adjuvant plan is settled.
Want the Molecular Testing Checked Before Deciding?
In Grade 3 disease it can change the recommendation in either direction, and it is done on tissue you have already given. The opinion is free.
What Treatment Usually Involves
More than for low-grade disease, and the specifics depend on stage and molecular group together.
- Surgery with thorough staging. Hysterectomy with tubes and ovaries, and node assessment performed more consistently than in low-grade disease because the chance of involvement is higher. See sentinel node biopsy.
- Radiation is usual. Vault brachytherapy for lower-risk cases, pelvic radiation where deep invasion, substantial vessel involvement or node involvement is present. See pelvic radiation.
- Chemotherapy in higher-risk cases. Particularly with deep invasion, node involvement, or a p53-abnormal result. Often given alongside radiation rather than instead of it. See chemotherapy.
- Possibly less, if POLE-mutated. The one situation where the recommendation may be to de-escalate. Worth establishing before a plan is finalised rather than afterwards.
- Fertility-sparing treatment is not an option here. It is confined to Grade 1 tumours with no muscle invasion. If you are young and this matters to you, that is a difficult conversation to have and it should be had directly. See who is eligible.
For how the decision is actually made and what weighs on it, see the adjuvant decision.
Why This Group Benefits Most From Complete Testing
Grade 3 is where the molecular result spreads outcomes widest — and where an untested tumour leaves the most on the table.
MMR / MSI testing as standard
Slides reviewed, not just the summary line
Tumour board for every diagnosis
Sentinel node mapping where it fits
Image-guided pelvic radiation
Decisions for healing, not billing
Take The Next Step
Ask About POLE by Name
It is the one result that can mean less treatment, and it is the one most often left undone.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Grade 3 Endometrial Cancer — Frequently Asked Questions
What does Grade 3 endometrial cancer mean?
It means more than half of the tumour grows as solid sheets of cells rather than forming the glandular structures that normal endometrium is made of — or that the cell nuclei look markedly abnormal in a way that raises the grade. Grade measures how far the tumour has drifted from the appearance of the tissue it arose in, and Grade 3 is the furthest of the three. In practice it correlates with more aggressive behaviour: a higher rate of deep invasion into the muscle wall, more lymphovascular space invasion, and a greater chance of lymph node involvement than Grade 1 or Grade 2 tumours at the same stage.
Is Grade 3 endometrioid cancer the same as Type 2?
No, though it is frequently managed alongside Type 2 disease, and that inconsistency causes real confusion. By histological type, Grade 3 endometrioid carcinoma belongs with the Type 1 endometrioid cancers — it still forms glands, just fewer of them. By behaviour it sits much closer to the non-endometrioid Type 2 cancers, with comparable rates of deep invasion and nodal spread, which is why treatment recommendations often group them. This mismatch between appearance and behaviour is one of the main reasons molecular classification has largely displaced the Type 1 and Type 2 model for clinical decision-making.
Why does molecular testing matter so much for Grade 3?
Because in this group the molecular result spreads outcomes wider than the grade itself does, and it can move the recommendation in either direction. A POLE-mutated Grade 3 tumour behaves exceptionally well despite its appearance, with very low recurrence rates, and European guidance supports de-escalating adjuvant treatment in early-stage POLE-mutated disease — one of very few molecular findings anywhere in oncology that leads to less treatment rather than more. Conversely, a p53-abnormal Grade 3 tumour is managed as high risk regardless of stage. Two women with identical-looking pathology can reasonably receive quite different recommendations on this basis.
Will I need chemotherapy as well as radiation?
It depends on stage and molecular group rather than on the grade alone. Radiation is usual for Grade 3 disease — vault brachytherapy for lower-risk cases, pelvic radiation where there is deep invasion, substantial lymphovascular space invasion or node involvement. Chemotherapy enters the discussion for higher-risk situations, particularly with deep invasion, involved nodes, or a p53-abnormal molecular result, and is often given alongside radiation rather than instead of it. If the tumour proves POLE-mutated and the stage is early, the recommendation may be to give less rather than more. This is a decision worth having made by a full tumour board.
Can I still have fertility-sparing treatment with Grade 3 disease?
No. Fertility-sparing treatment — keeping the uterus and using high-dose progestin instead of surgery — is confined in international guidance to Grade 1 endometrioid tumours confined to the lining with no invasion into the muscle wall. The reason is that the approach depends on the tumour being both hormone-responsive and genuinely contained, and Grade 3 tumours are considerably less likely to be either. If you are young and this matters to you, it deserves a direct and honest conversation with your team rather than being left unaddressed, including a discussion of what other fertility options may exist before treatment begins.
Medical disclaimer: This page explains Grade 3 endometrioid endometrial cancer in general terms and is reviewed by a CION oncologist, following the FIGO staging system, the World Health Organization classification, and current NCCN and ESGO–ESTRO–ESP guidance. It describes tumour behaviour at a population level and does not predict an outcome for any individual. Treatment decisions should be made with the oncology team holding your full pathology and molecular testing results.